Coronary anatomy is key for arterial switch operations as reimplantation for coronary artery patterns originating from the same sinus is often challenging. We experienced an extremely rare coronary artery anatomy case (Leiden convention: 1 R, 1LCx) and successfully performed an arterial switch operation with coronary button extension and neo-pulmonary trunk realignment maneuver.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jocs.17188 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Switch after Switch. Ventricular retraining as alternative to heart transplant].
Andes Pediatr
October 2024
Departamento de Cardiopatías Congénitas y Pediátricas, Fundación Cardiovascular de Colombia, Santander, Colombia.
Unlabelled: Transposition of the great arteries (Dextro-TGA), repaired with physiological correction techniques (atrial switch - Mustard or Senning surgery), can present as a complication the failure of the right ventricle that acts as systemic and, at the same time, deconditioning of the left ventricle, leading to congestive heart failure. In these patients, treatment and recovery options are very limited.
Objective: To describe successful late anatomical correction after ventricular retraining.
Propensity Score Analysis of Possible Medication Effects on Outcomes in Patients With Systemic Right Ventricles.
JACC Adv
January 2025
Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon, USA.
Background: Patients with systemic right ventricle (SRV), either d-transposition of the great arteries following an atrial switch procedure or congenitally corrected transposition of the great arteries, develop severe right ventricular dysfunction, prompting appropriate medical therapy. However, the efficacy of beta-blockers and angiotensin receptor blockers or angiotensin-converting enzyme inhibitors (ACEI) in SRV patients is unproven.
Objectives: The objective of this study was to determine the effects of ACEI/ARB and beta-blockers on outcomes in SRV patients after accounting for likely cofounders affecting their use.
Magnolia kobus DC. suppresses neointimal hyperplasia by regulating ferroptosis and VSMC phenotypic switching in a carotid artery ligation mouse model.
Chin Med
January 2025
Aging and Metabolism Research Group, Korea Food Research Institute, Wanju‑gun, 55365, Republic of Korea.
Background: Magnolia kobus DC (MO), as a plant medicine, has been reported to have various physiological activities, including neuroprotective, anti-inflammatory, and anti-diabetic effects. However, vascular protective effects of MO remain incompletely understood. In this study, we evaluated the vascular protective effect of MO against ferroptosis in a carotid artery ligation (CAL)-induced neointimal hyperplasia mouse model and in aortic thoracic smooth muscle A7r5 cells.
View Article and Find Full Text PDFPlatelet membrane decorated exosomes enhance targeting efficacy and therapeutic index to alleviate arterial restenosis.
Theranostics
January 2025
Department of Vascular Surgery, Zhongshan Hospital Fudan University, Shanghai, 200032, PR China.
Article Synopsis
- Postinterventional restenosis poses challenges in treating peripheral vascular disease, as current drugs hinder endothelial repair while preventing neointima hyperplasia.
- Stem cell-derived exosomes offer therapeutic benefits by delivering functional microRNAs but face limitations in targeting and tissue uptake in injured vessels.
- To improve efficacy, researchers created platelet-mimetic exosomes (PM-EXOs) that enhance targeting to vascular injuries and promote endothelial repair with minimal side effects, demonstrating significant potential in reducing neointima formation.
Safety, tolerability, and efficacy of an in-class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary arterial hypertension.
Pulm Circ
October 2024
UK Service for Pulmonary Hypertension in Children, Great Ormond Street Hospital for Children London UK.
The aim of this single-centre retrospective observational study was to evaluate the safety, tolerability, and efficacy of an in-class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary arterial hypertension. Children aged over 5 years who were established on sildenafil plus bosentan were offered to undergo a therapy switch from May 2014 to May 2021 and, if remaining in the service, followed up to May 2024. Children with Eisenmenger syndrome, open intra or extra-cardiac shunt, or with pulmonary hypertension-associated lung disease were excluded.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!